Imperial College London

Professor Anthony Gordon

Faculty of MedicineDepartment of Surgery & Cancer

Chair in Anaesthesia and Critical Care
 
 
 
//

Contact

 

+44 (0)20 3312 6328anthony.gordon

 
 
//

Location

 

ICUQueen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Collaborators

International Severe Acute Respiratory and Emerging Infection Consortium

UK Critical Care Genomics Group

International Forum for Acute Care Trialists

Guest Lectures

"Personalised Medicine in Sepsis""Cardiovascular Management in Sepsis""New Treatment Strategies for Sepsis", SG-ANZICS - Asia-Pacific Intensive Care Forum, Singapore, 2018

"Biomarkers in sepsis - Improved Phenotyping" "Vasoactive drugs in septic shock - Alternatives to Catecholamines" "How we decide - Why don't all ICUs use selective digestive decontamination (SDD)?", The International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 2016

Sepsis - How might we improve the outcome?, Swedish Society for Anaesthesiology and Intensive Care, Stockholm, Sweden, 2015

REDUCING THE GLOBAL BURDEN OF SEPSIS: DEVELOPING A ROADMAP. SDD / SOD and prevention of sepsis in the ICU, International Sepsis Forum Colloquium and International Symposium on Intensive Care and Emergency Medicine Roundtable, Brussels, Belgium, 2015

“How should we use vasopressin in septic shock” and “New ICU Clinical Trials for 2015”, Scottish Intensive Care Society, St Andrews, Scotland, 2015

Why don’t we use selective decontamination?, Intensive Care Society “State of the Art Meeting”, London, 2013

New Knowledge in Critical Care – Sepsis, Faculty of Intensive Care Medicine, London, 2013

"Interactions between vasopressin and steroids" and "Biomarkers in sepsis: Metabolic profiles", 33rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 2013

Advances in Sepsis Management, Royal College of Anaesthetists, London, 2013

Outcomes in Critical Care Research, UK Critical Care Research Forum, Belfast, 2012

How should we use vasopressin in septic shock?, UK-China Anaesthesia Summit Forum, Bejing, China, 2012

Genomics from science to clinical practice, Intensive Care Society, State of the Art meeting, London, 2011

Controversies regarding hypothermia and vasopressors, Elisabeth Edén Symposium, Traumatic Brain Injury, Gothenburg, Sweden, 2011

“Sepsis: Controversial therapies – Vasopressin” and “Pro-con debate - Vasopressin before catecholamines in septic shock”, 31st International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 2011

Septic shock – latest thoughts, Intensive Care Society “State of the Art Meeting”, London, 2010

Can genetic profiles inform clinical management in intensive care?, British Association of Parenteral and Enteral Nutrition annual conference, Harrogate, 2010

Role of TNF and TNFR polymorphisms in the outcome from severe sepsis & septic shock: lessons from a clinical study, Royal Society of Medicine, 2002

Vasopressin in Septic Shock, Anglia Ruskin University, 2009

Who benefits from Intensive Care? - Cancer and Critical Care Outcomes, Intensive Care Society, Royal College of Anaesthetists, 2009

Genetic predictors of response to activated protein C, Intensive Care Society “State of the Art Meeting”, London, 2007

Sepsis Masterclass - Genetics of sepsis, West Midlands Intensive Care Society, Coventry, 2008

“Genetics of activated protein C” and“The effect of vasopressin on renal function in septic shock”, Critical Care Canada Forum, Toronto, 2007

Research Student Supervision

Antcliffe,DB, Metabolic Signatures of Pneumonia in Perioperative and Critical Care: A Paradigm Shift in Diagnosis and Therapeutic Monitoring

Davies,R, Investigating the human inflammatory response in sepsis and sterile injury using an in vitro migration assay to assess monocyte immune function

Komorowski,M, Dynamic mortality prediction and decision support system in the ICU

McLymont,N, Metabolic signatures of sepsis in critical care: an individualised approach to diagnosis and management

O'Callaghan,DD, Mechanisms of monocyte priming and tolerance in vitro and in vivo involving tumour necrosis factor-alpha converting enzyme

Woodbridge,H, When should clinicians start early mobilisation on intensive care? Exploring the barriers to early mobilisation and developing tools to study the safety of mobilisation of Intensive Care Unit patients.